ClinicalTrials.gg
RecruitingNCT06526208Updated Mar 30, 2026

Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults

A Phase 2 interventional study of MB-IMP and Placebo in Autism Spectrum Disorder and Anxiety, sponsored by Southwest Autism Research & Resource Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Southwest Autism Research & Resource Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 604 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Planned enrollment
112th of 505
108 · median 44
Started
2025
with 25 others
Phase 2
95 of 604
11 open now
Primary completion
2026-09
later than 38 of 150 live
Registered
514th of 604
by date

Among the 604 studies in Autistic Disorder with a site in United States, this one is the 112th largest by planned enrollment of the 505 interventional ones that give a count, is one of 26 that started in 2025, is one of 95 in phase 2, reaches primary completion later than 38 of the 150 other live ones, and was the 514th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 604 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 604 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC. The main questions it aims to answer are:

Will a marijuana-based drug help anxiety in autistic adults?

Anxiety can make socializing and working more difficult for people. Researchers will compare a marijuana based drug (that is mostly CBD with a small amount of THC) to a placebo (a look-alike substance that contains no drug) to see if the drug makes symptoms of anxiety better.

Participants will take the drug (or a placebo) every day for 8 weeks and keep a diary to record the time they took the drug, and their feelings each day. The drug is taken orally in drops once or twice a day. The study staff will speak to the participants weekly either over the phone or in the clinic. Clinic visits once every 2 weeks for checkups and tests. The researchers will make sure participants are healthy and see if there are any changes in anxiety.

Read the detailed description

The marijuana-based investigation medical product (MB-IMP) in this study is 23 parts CBD and 1 part THC. The placebo is medium chain triglyceride oil. MB-IMP or placebo will be taken orally. DSM-5 diagnosis of autism spectrum disorder will be confirmed with Autism Diagnostic Observation Schedule, version 2, and review of medical records. History of psychosis, suicidality, cardiac or hepatocellular issues may be exclusionary. The participant must have a study partner who will complete observational assessments regarding the participant\'s behavior.

The screening period is 3 weeks to allow for lab results and medical records to be obtained. The active phase of the study (on drug or placebo) is 8 weeks, and their will be one follow-up visit after 14 days off drug.

03

Conditions studied

  • Autism Spectrum Disorder
  • Anxiety

Browse trials for

Keywords

  • Autism
  • Anxiety
  • marijuana
  • cannabis
  • CBD
  • THC
04

In context

Autistic Disorder Reclassified

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

This study's planned enrollment of 108 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Southwest Autism Research & Resource Center is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female age 18 to 45 years old with an autism diagnosis.
  2. Participant is ≥ 100 lbs.
  3. Participant or a legally authorized representative provides /assent for participation in the trial.
  4. Participant/caregiver is willing and able to comply with all study procedures.
  5. Participant meets ADOS-2 criteria for Autism or Autism Spectrum
  6. Participant meets criteria for ASD.
  7. Participant has a minimum CGI-S (Anxiety) score ≥ 5 based on anxiety related social functional impairment.
  8. Participant has a FSIQ ≥ 65 at screening measured with the WASI- II, or within 1 year of screening with a comparable assessment.
  9. Participant must have a negative pregnancy test (urine and serum) at Screening, and a negative urine test at Baseline, Active Phase Visits, and EoS visits, see Table 1. Schedule of Activities.
  10. Sexually active participants agree to use two methods of effective , as described in Appendix B: Contraceptive and Barrier Guidance during the study intervention period and for at least 14 days after the Study Termination visit.
  11. Participant must be stable on any pre-study medications and/or psychotherapy for 6-weeks prior to study enrollment, agree to inform prescribing clinician(s) about participation in the study, and agree to maintain medication or psychotherapy treatment regimen during the study.
  12. Participant must be able to ingest MB-IMP (or placebo) and be willing to commit to medication dosing and completing the dosing diary.
  13. Participant/caregiver agrees to keep all study medication provided by site staff securely stored at home and not to share/distribute study medication to any other individual.
  14. Participant agrees not to participate in any other interventional clinical trials during the study period.
  15. Participant agrees to inform the investigators within 48- hours of any side-effects, medical conditions, and procedures.
  16. Participant agrees to abstain from alcohol use during the study.

Exclusion criteria

Exclusion Criteria:

  1. Participant weighs \< 100 lbs.
  2. Participant is sexually active and does not practice two effective forms of .
  3. Participant is pregnant, lactating, or planning pregnancy during the study period or within 12 weeks thereafter.
  4. Participant has a current or historical psychotic features/disorder assessed via the Mini-International Neuropsychiatric Interview (MINI).
  5. Participant has a current or historical diagnosis of dissociative identity disorder, positive family history (first-degree relative) of psychotic disorder or bipolar disorder type 1.
  6. At high risk of suicide or suicide attempts.

    1. Individuals presenting current serious suicide risk, as determined through psychiatric interview, responses to the Columbia Suicide Severity Rating Scale (C-SSRS), and/or clinical judgment of the investigator.
    2. History of suicide attempts within 12 months prior to study enrollment.
  7. Participant has a current substance use disorder within the 12 months prior to enrollment as determined by the MINI Kid56.
  8. Participant's urine drug screen is positive for opiates, methamphetamine, cocaine, THC, and amphetamines (unless prescribed). Participants with positive THC urine analysis tests are excluded from the study but will be allowed to rescreen (maximum twice) after a 1-month cessation of cannabis use.
  9. Participant has a history of arrhythmia, other than occasional premature atrial contractions (PACs) and premature ventricular contractions (PVCs) without ischemic heart disease, within 12 months of screening.
  10. Participant with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia, or any other arrhythmia associated with a bypass tract, may be enrolled only if they have been successfully treated with ablation and have not had a recurrent arrhythmia for at least one year off all antiarrhythmic drugs or are under adequate and stable pharmacologic treatment for atrial fibrillation for at least a year, as confirmed by a cardiologist.
  11. Participant has a current diagnosis or evidence of significant or uncontrolled hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, gastrointestinal, renal, immunocompromising, or neurological disease according to PI's discretion.
  12. Evidence of existing hepatocellular injury defined as (ALT) and aspertate aminotranferase (AST) elevations of greater than 3 times upper limit normal () and elevation of greater than 2 times ULN.
  13. The PI or medical monitor deems the participant inappropriate for the study for any reason.
  14. Any known allergies/sensitivities to cannabis (in the opinion of the investigator).
  15. Not able to attend required face-to-face visits or those who plan to move out of the area within the treatment period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    MB-IMP Group

    Participants in this group will receive the MB-IMP, an oil-based solution that will contain CBD and THC (23:1 ratio, respectively) and be taken orally. Participants or study partners will dispense the daily dose with an eye dropper according to instructions from the Principal Investigator or delegated study coordinator. Dosing will start at 0.25 ml per day (50 mg of CBD and 2.18 mg of THC). The dose will gradually increase to 1.0 ml per day (200 mg of CBD, and 8.7 mg of TCH) by week 4. Weeks 5 through 8 will be at the maximum dose, 2 ml per day (400 mg of CBD and 17.4 mg of THC). With the exception of week 1 at the lowest dose (0.25 ml), participants will dose in the morning and evening to reach the maximum dose for that time period.

    Drug: MB-IMP

  • Placebo comparator
    Placebo Group

    Participants will follow the same dosing instructions for the MB-IMP group, but will take only MCT oil.

    Other: Placebo

Interventions

  • DrugMB-IMP

    MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.

    Also known as: MCT oil

  • OtherPlacebo

    Does not contain CBD or THC

    Also known as: Medium Chain Triglyceride (MCT) oil

07

What researchers measure

Primary outcomes

  1. Change in baseline on reported anxiety related symptoms

    The Clinical Global Impression Scale for Severity will be used to measure the change in anxiety related symptoms. We hypothesize a two point reduction in severity and

    Time frame: 8 weeks

Secondary outcomes

  1. Change in socialization

    We will measure the Change in behaviors related to socialization with the Social Responsiveness Scale

    Time frame: 8 weeks

  2. Change in repetitive behaviors from baseline to the end of study

    We will measure the amount of repetitive behaviors with the Repetitive Behavior Scale- Revised

    Time frame: 8 weeks.

  3. We will measure the change in a variety of aberrant behaviors from baseline to end of study

    Study partners will complete the Aberrant Behavior Checklist at every clinic visit.

    Time frame: 8 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2026, 16 months after the start.

Of 36 non-industry phase 2 interventional studies under Autistic Disorder, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 16 months is below that.

Counting every sponsor, half of 45 studies reached it within 39 months; a quarter within 24 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Jul 29, 2024
StartActual
May 28, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2027
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06526208
Lead sponsor
Southwest Autism Research & Resource Center
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
May 28, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Christopher J Smith, Ph.D.
Contact
csmith@autismcenter.org
602-218-8192
Brian Shaw
Contact
bshaw@autismcenter.org
602-340-8717
Christopher J Smith, Ph.D.
principal investigator · SARRC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion